Viking phase 2b study of NASH candidate hits primary endpoint

A phase 2b trial of Viking Therapeutics' ( NASDAQ: VKTX ) VK2809 found that those on the medicine saw statistically significant reductions in liver fat, meeting the primary endpoint. At week 12, the mean relative change from baseline ranged from 37% to 55%. The response rate.